Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer

Xiaoliang PANG; Kosuke TASHIRO; Rieko EGUCHI; Nobukazu KOMATSU; Tetsuro SASADA; Kyogo ITOH; Satoru KUHARA

doi:10.1271/bbb.120893

Biochemistry & Molecular Biology Regular Papers

Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer

Xiaoliang PANG, Kosuke TASHIRO, Rieko EGUCHI, Nobukazu KOMATSU, Tetsuro SASADA, Kyogo ITOH, Satoru KUHARA

Author information

Keywords: haptoglobin, peripheral blood mononuclear cells, castration-resistant prostate cancer, treatment by cancer peptide vaccine

JOURNAL FREE ACCESS

2013 Volume 77 Issue 4 Pages 766-770

DOI https://doi.org/10.1271/bbb.120893

View "Advance Publication" version (April 7, 2013).

Details

Abstract

Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in short-term survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.

Corresponding author

Register with J-STAGE for free!